Boston Scientific Corp. (BSX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Boston Scientific Corp. (BSX)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Key Insights
Critical company metrics and information
Share Price
$90.07Market Cap
$132.75 BillionTotal Outstanding Shares
1.47 Billion SharesTotal Employees
48,000Dividend
No dividendIPO Date
May 18, 1992SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.bostonscientific.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $2.00 Million |
| Net Cash Flow From Investing Activities, Continuing | $-3.04 Billion |
| Net Cash Flow From Investing Activities | $-3.04 Billion |
| Net Cash Flow From Financing Activities | $1.61 Billion |
| Net Cash Flow, Continuing | $1.51 Billion |
| Net Cash Flow From Operating Activities, Continuing | $2.94 Billion |
| Net Cash Flow | $1.52 Billion |
| Net Cash Flow From Financing Activities, Continuing | $1.61 Billion |
| Net Cash Flow From Operating Activities | $2.94 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $2.20 Billion |
| Basic Earnings Per Share | $1.22 |
| Net Income/Loss Attributable To Parent | $1.79 Billion |
| Income Tax Expense/Benefit | $414.00 Million |
| Revenues | $15.91 Billion |
| Net Income/Loss | $1.79 Billion |
| Diluted Earnings Per Share | $1.21 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Selling, General, and Administrative Expenses | $5.75 Billion |
| Basic Average Shares | $1.47 Billion |
| Operating Expenses | $8.46 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $-18.00 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $1.79 Billion |
| Gross Profit | $10.97 Billion |
| Income/Loss From Continuing Operations After Tax | $1.79 Billion |
| Other Operating Expenses | $2.71 Billion |
| Operating Income/Loss | $2.51 Billion |
| Interest Expense, Operating | $290.00 Million |
| Benefits Costs and Expenses | $13.71 Billion |
| Cost Of Revenue | $4.94 Billion |
| Diluted Average Shares | $1.49 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Costs And Expenses | $13.71 Billion |
| Nonoperating Income/Loss | $-311.00 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Assets | $38.08 Billion |
| Current Liabilities | $5.91 Billion |
| Liabilities And Equity | $38.08 Billion |
| Other Non-current Assets | $20.49 Billion |
| Equity | $20.96 Billion |
| Fixed Assets | $3.07 Billion |
| Noncurrent Assets | $29.32 Billion |
| Accounts Payable | $907.00 Million |
| Liabilities | $17.12 Billion |
| Noncurrent Liabilities | $11.21 Billion |
| Wages | $1.11 Billion |
| Other Current Assets | $6.01 Billion |
| Current Assets | $8.76 Billion |
| Inventory | $2.75 Billion |
| Intangible Assets | $5.75 Billion |
| Other Current Liabilities | $3.89 Billion |
| Equity Attributable To Noncontrolling Interest | $248.00 Million |
| Equity Attributable To Parent | $20.71 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Boston Scientific Corp. (BSX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.